Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$42.00
-2.20 (-4.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 31% · confianza 25%
FCF escenarios
weak_data · normalized FCF $67.1M · quality 71.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
127.3x
↑EV/EBITDA
20.3x
↑ROE
1.5%
↑Gross Margin
71.3%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-24.8%
FCF CAGR
-65.0%
FCF margin
2.2%
FCF / Net income
2.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $794.2M · net income $7.7M · FCF $17.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $794.2M | $794.2M | $573.6M | $618.8M | $1.87B |
| Net Income | $7.7M | $7.7M | $89.1M | $162.9M | $281.3M |
| EBITDA | $47.0M | $47.0M | $146.4M | $185.9M | $553.8M |
| EPS | — | — | 4.18 | 5.75 | 11.49 |
| Gross Margin | 71.3% | 71.3% | 74.0% | 78.1% | 55.7% |
| Operating Margin | 1.9% | 1.9% | 18.9% | 24.3% | 20.7% |
| Net Margin | 1.0% | 1.0% | 15.5% | 26.3% | 15.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.25 | 0.01 | 0.02 |
| Current Ratio | 3.55 | 3.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $17.1M | $17.1M | $112.8M | $67.1M | $400.4M |
| Returns | |||||
| ROE | 1.5% | 1.5% | 16.7% | 34.2% | 44.2% |
| Valuation | |||||
| P/E | 127.27 | 127.27 | 12.47 | 21.41 | 11.47 |
| EV/EBITDA | 20.29 | 20.29 | 8.12 | 14.97 | 5.14 |
| P/B | 2.02 | 2.02 | 2.38 | 6.31 | 5.07 |
| Growth & Yield | |||||
| Revenue Growth | 38.5% | 38.5% | -7.3% | -66.8% | — |
| EPS Growth | — | — | -27.3% | -50.0% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.8%
Start / end P/E
n/dx → n/dx
EPS bridge
4.18 → n/d
Residual
-38.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.